Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.60
- Piotroski Score 3.00
- Grade Neutral
- Symbol (BOLT)
- Company Bolt Biotherapeutics, Inc.
- Price $0.57
- Changes Percentage (1.33%)
- Change $0.01
- Day Low $0.56
- Day High $0.58
- Year High $1.56
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
- Last Earnings 08/13/2014
- Ex-Dividend for 5/16 Dividend 08/29/2014
- Dividend Payable 10/02/2014
- Today N/A
- Next Earnings (Estimated) 03/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $1.00
- High Stock Price Target $1.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.66
- Trailing P/E Ratio -0.46
- Forward P/E Ratio -0.46
- P/E Growth -0.46
- Net Income $-69,197,000
Income Statement
Quarterly
Annual
Latest News of BOLT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Phillies 2024 Trade Acquisition Projected To Bolt To NL West Contender
The Philadelphia Phillies traded top pitching prospects for Carlos Estévez in 2024. Now a free agent, Estévez is projected to sign a $42 million contract. Speculation suggests he may join the Arizon...
By Newsweek | 1 day ago -
Padres' $14 Million Shortstop Predicted to Bolt for Rival Dodgers
The San Diego Padres and Los Angeles Dodgers have a fierce rivalry, with the Dodgers often dominating. There's speculation that the Dodgers might sign Padres shortstop Ha-Seong Kim in free agency, as ...
By Newsweek | 5 days ago -
Uber rival Bolt's annual revenue hits 2 billion euros
Estonian startup Bolt reaches 2 billion euros in annual revenue, expanding globally and planning to go public. Offering ride-hailing, food delivery, and more in 50 countries, the company aims to innov...
By Yahoo! Finance | 1 week ago
